Skip to main content
. Author manuscript; available in PMC: 2012 Aug 28.
Published in final edited form as: J Cell Sci. 2011 Jan 18;124(Pt 4):556–564. doi: 10.1242/jcs.076745

Figure 6. Antitumor effects induced by peritumoral injection of R8-Bax[106-134] in TS/A-pc mammary carcinoma xenografts.

Figure 6

Mouse mammary TS/A-pc carcinoma growth inhibition by Bax[106-134]. Three days after injection of tumor cells, mice (9 mice/group) received vehicle (PBS), 100 μg of Bax[106-134], or 100 μg of Bax-Scr peritumorally, 5 times a week for 2 weeks (arrows). Tumor volumes are indicated as mean values ± S.E.M. The tumor doubling times (Days ± S.E.M) were 0.493 ± 0.034 for the control group (P vs. Scramble = 0.7963, not significant), 0.692 ± 0.055 for the R8-Bax[106-134] group (P vs. control = 0.0072 **/P vs. Scramble = 0.0063 **) and 0.480 ± 0.039 for the R8-Bax[Scr] group (P vs. control = 0.7963, not significant). Inset: protein levels of active caspase-3 in tumor extracts from each group were determined by immunoblotting. To ensure equal protein loading, membranes were also probed for tubulin. Data from triplicate samples are shown.